Dave, the model could change at any point in regards to MANF. Today we partner with Universities and license the IP. What if we licensed MANF for upfront money and a percentage of revenue. The longer someone waits, the more they pay. Could be a lucrative model down the road, with less work on the companies end.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links